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Abstract: According to the World Health Organization, globally 4.9 million are blind due 
to corneal pathology. Corneal transplantation is successful and curative of the blindness for 
a majority of these cases. However, it is less successful in a number of diseases that produce 
corneal neovascularization, dry ocular surface and recurrent inflammation, or infections. 
A keratoprosthesis or KPro is the only alternative to restore vision when corneal graft is a doomed 
failure. Although a number of KPros have been proposed, only two devices, Boston type-1 
KPro and osteo-odonto-KPro, have came to the fore. The former is totally synthetic and the 
latter is semi-biological in constitution. These two KPros have different surgical techniques and 
indications. Keratoprosthetic surgery is complex and should only be undertaken in specialized 
centers, where expertise, multidisciplinary teams, and resources are available. In this article, we 
briefly discuss some of the prominent historical KPros and contemporary devices.
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Introduction
Keratoprosthesis (KPro) is an ancient idea; it predates the origin of corneal 
transplantation. In the eighteenth century, guided by an expanding knowledge in 
human anatomy along with a surge in empirical approach to medicine, the earlier 
physicians were able to gradually recognize corneal diseases as a specific cause for 
blindness. While the clinical assessment and investigation methodologies for the 
disease evaluation were still nascent, interestingly, preliminary attempts for treating 
corneal blindness began with artificial materials as a means of corneal substitution. 
Sadly, these trials were plagued with severe failures mainly due to the lack of parallel 
developments in the biomaterials, surgical instruments, and techniques. With the 
evolution of corneal transplantation that was more promising than the artificial 
implants, unsurprisingly, interest in KPros had wilted. Although corneal grafts may 
have a life span of some decades in low-risk cases, the visual gain may be limited by 
astigmatism and complications; and, even in successful cases, visual recovery fol-
lowing grafting can be protracted.1,2 Over the years, limitations of the corneal grafts 
have surfaced; it is now well recognized that they do not offer a lasting solution to 
corneal blindness.
A corneal transplant carries a lifetime risk of rejection and failure. Despite the 
improvements in corneal lamellar surgical techniques and limbal stem cell transplanta-
tion, and a widespread usage of immunosuppression, graft survival has not improved 
in autoimmune diseases, chemical injuries, and dry eyes.3–5 Thus, the place for KPros 
is well preserved. In this article, we endeavor to succinctly describe some of the 
prominent and contemporaneous KPros and their performance.
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Need for KPros
In a recent estimate, the World Health Organization identi-
fies that globally 4.9 million people are bilaterally corneal 
blind, which accounts for 12% of the total burden of global 
blindness (39 million).6–8 By extrapolation of this data, it can 
be inferred that there could be a significant proportion of uni-
laterally corneal blind people living in the world at present.6 
These estimates also indicate that worldwide, a large number 
of people could benefit from corneal transplantation.
Corneal grafting is proven to be one of the highly success-
ful solid organ transplantations. A lamellar or full-thickness 
corneal graft is performed to restore vision when the host 
corneal transparency is lost in a disease process. During the 
first few years after the transplantation, corneal graft survival 
is generally high. The Australian Corneal Graft Registry 
(ACGR) and NHS Blood and Transplant authority reported a 
survival rate in the first year as 87% and 93%, respectively.9,10 
 Five-year transplant survival rate for the penetrating grafts 
in the former was 73% and in the latter 72%.9,10 According 
to the Australian report, the survival of lamellar transplants 
in the first year was 80%.9 It also reported that after 15 years, 
the transplant survival rates had steadily fallen to 46% for the 
full-thickness grafts and 41% for lamellar grafts.9
Corneal transplantation is a well-known successful proce-
dure for a number of conditions such as keratoconus, corneal 
opacities, and bullous keratopathy.11 However, viability of 
corneal grafts in recurrent and chronic inflammatory conditions 
such as sicca disease states and herpetic infections, and in vas-
cularized corneal beds is low.5,11 Keratolimbal and limbal stem 
cell allografts performed for conditions associated with severe 
limbal stem cell deficiency are also constrained by limited suc-
cess and frequently require immunosuppression for survival.12,13 
In a majority of these situations, a KPro is the only available 
option to traverse the ocular surface in order to restore vision.
Globally, availability of corneal donor material is limited, 
especially in developing countries. In addition, facilities for 
processing, preservation, storage, and supply of the trans-
plantable tissues are a challenge for many nations, again 
principally for the developing countries.6 Besides, biological 
tissue transplants carry a risk of transmissible diseases such 
as blood-borne infections, Creutzfeldt-Jakob disease (CJD), 
tuberculosis, hepatitis C, and venereal infections. It is pleas-
ing to consider that an artificial cornea could eliminate the 
problems associated with corneal allografts; however, at 
present, KPro is not an alternative to routine corneal trans-
plantation. A KPro is indicated only in end-stage corneal 
blindness due to conditions such as severe ocular surface 
disease and multiple graft failures – principally when con-
ventional transplantation is a destined failure.
History and development of KPros
Pellier de Quengsy was the first to record his ideas of a 
KPro that consisted of a convex glass plate surrounded by a 
silver rim.14 Nussbaum described a collar-stud glass device 
with two plates that sandwich the corneal tissue, which 
are also connected in the center by an optical cylinder.14,15 
He performed animal experiments with his KPro and also 
implanted in humans. Heuser implanted a KPro made of 
quartz material and implanted in humans.16 Abbate applied a 
skirt made of milk protein and rubber to the glass and inserted 
in animals.16 Although it was extruded shortly afterward, 
his efforts emphasized the importance of a skirt material for 
better tissue incorporation of the KPro. Salzer experimented 
with a quartz crystal enclosed in a platinum ring with prongs, 
and he also recognized the importance of a skirt material.16 
Celluloid was used in a hat-shaped KPro model by Dimmer 
as a first polymeric biofunctional implant.14
Interest in synthetic corneal replacements was declined 
in the early part of the last century, largely due to the rise 
of cadaveric corneal transplantation. In addition, the exist-
ing KPros were not successful. With the breakthrough 
discovery of polymethylmethacrylate (PMMA), as a poten-
tially implantable material in the eye, interest in KPro was 
rekindled.17 PMMA has fulfilled the need for a stable and 
biocompatible optic. Gradually, a two-part “core–skirt” 
skeleton for the KPro was recognized.18–20 Choyce and Stone 
developed a two-piece KPro independently.18,20
Dohlman et al introduced a collar-button model made 
of PMMA.21 Ruedemann devised a satellite-shaped optical 
piece made of silicone attached to a Dacron skirt.22 Cardona 
developed a two-piece nut-and-bolt KPro.19 He also used a 
pigmented PMMA cylinder with a fenestrated Teflon skirt 
in a later design.23 Another essential contribution by Car-
dona was to project the optic through the lid in extremely 
dry ocular surfaces.23 Girard developed a KPro similar to 
Cardona’s nut-and-bolt device but used Proplast as a skirt 
material.24 Polack developed a KPro made of a ceramic 
skirt, which was implanted external to the cornea.25 In 
some cases, the optic was also projected outside the lids.25 
Caldwell developed a softer skirt material made from poly-
urethane.26 Worst et al prepared a rivet-shaped champagne 
cork KPro and sutured it to the sclera using steel wires.26,27 
Pintucci et al developed a KPro made of a PMMA optic 
and a Dacron skirt.28,29 This device is implanted in two 
stages. Labial or cheek mucous membrane covers the ocular 
surface in stage-1. The device is buried in the submuscu-
lar pouch for 2–3 months before its implantation into the 
eye (Figure 1). Readers are advised to refer to Table 1 for 
further details on historical KPros.
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Figure 1 Pintucci KPro.
Notes: (A) Pintucci KPro device. (B) First stage – insertion of Pintucci device into submuscular pouch for vascular ingrowth. (C) First stage – covering the ocular surface 
with buccal/labial mucosa. (D) Second stage – implantation of the retrieved device into the eye (2–3 months after the stage 1). (E) Second stage – creating an opening in the 
buccal mucosa to expose the optic. (F) Postoperative appearance of a successful Pintucci KPro. All pictures of this figure are the courtesy of Dr Qureshi Maskati.
Abbreviation: KPro, keratoprosthesis.
Chirila et al noted that investigators have tried polymers 
other than PMMA as optical components for their KPros 
such as the following: silicone by Ruedemann, polysiloxane 
by Liebel, silicone rubber by Dohlman, polyvinyl alcohol 
hydrogels by Ikada, and polycarbonate by Worst, Singh, 
and Andel group (champagne cork KPro).16 Various porous 
skirts made of Proplast (Barber), Teflon (Legeais et al), 
hydrogels (Crawford et al), poly-2-hydroxyethyl methacry-
late (Mester), and silicone-carbon (Kain) were also tried 
with the intention of promoting better tissue integration.30–34 
All of the above devices have not shown promising results 
over the long term but failed with common problems such 
as extrusions, tissue melts, infections, and retinal detach-
ments, which primarily arise due to the lack of permanent 
bio-integration.30,35
Though a variety of KPros were proposed, essentially, 
they can be grouped into three basic categories based on their 
fixation method in the eye: 1) a collar-stud device sandwiches 
cornea between the two skirt plates (eg, Boston KPro), 
2) an intracorneal device secures the skirt inside the corneal 
stromal layers (eg, AlphaCor), and 3) an epicorneal device 
is held on the surface of the cornea and sclera (eg, osteo-
odonto-KPro [OOKP], Pintucci KPro). In general, these 
devices have a central core that is a transparent optical portion 
that transmits the light to the retina. Although a number 
of materials, models, and techniques were described, only 
two prostheses, the Boston type-1 KPro (Boston KPro) and 
OOKP, have proven successful.36 Yet, these devices neces-
sitate multiple surgical revisions and can give rise to severe 
complications. Thus, the search for an ideal KPro continues, 
which still remains elusive.37
General considerations for KPro 
surgery
A KPro is indicated to restore vision in cases of corneal 
blindness only when corneal transplantation has failed or 
runs a high risk for failure. Patients being considered for 
a KPro should be carefully evaluated for their suitability. 
Often, these patients would have had received multiple cor-
neal grafts, ocular surface, and lid reconstruction procedures 
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before being referred to the KPro surgeon. Hence, knowledge 
of the underlying diagnosis, present condition of the eye, 
previous treatments including the number and types of 
ocular surgeries and use of steroids, or immunosuppression 
is required for planning a management strategy. During 
the initial assessment, amount of surface scarring, forniceal 
shortening, and surface keratinization should be noted. The 
baseline tear secretion should also be quantified in order 
to determine the choice of KPro. These patients may have 
associated lid abnormalities, which could influence the choice 
of KPro and surgical approach. As a general rule, wet and 
blinking eyes with adequate tear production may be suitable 
for Boston type-1 KPro, whereas dry and keratinized eyes 
with impaired blinking and associated lid abnormalities 
should be considered for OOKP. The ability to apply and 
retain soft contact lens must be determined if a Boston type-1 
KPro is considered.15
Glaucoma is a frequent association with the ocular surface 
disease. Multiple mechanisms may contribute to the develop-
ment of glaucoma: the primary disease process may involve 
the trabeculum, the irido-corneal angle can be narrowed by 
the development of synechiae, and conjunctival scarring and 
surface keratinization can limit episcleral venous drainage. In 
addition, frequent use of steroids can contribute further to the 
occurrence of new-onset glaucoma and progression of exist-
ing glaucoma. Detection of glaucoma (and its  progression) 
can be difficult in ocular surface disease due to poor view of 
the fundus and inaccuracy in measuring intraocular pressure 
(IOP).
Fundal examination is usually not feasible in these 
patients due to opacities of the cornea and media.
An anterior segment optical coherence tomography 
(OCT) or ultrasound biomicroscopy should be performed 
to determine the status of anterior segment structures and 
irido-corneal angles before planning for surgery. The surgeon 
should look for and document the presence of corneal 
thinning, scars, sequelae of previous perforations, signs 
of previous glaucoma surgery such as glaucoma tubes and 
blebs, the amount of corneal neovascularization, status of 
the lens and iris, and evidence of vitreoretinal procedures in 
order to plan the necessary surgical steps to be undertaken. 
The presence or absence of the lens, and axial length of the 
globe are essential to know in order to determine the choice 
of Boston type-1 KPro (phakic or aphakic model), and power 
of the optical cylinder in OOKP surgery.15,38
Visual potential needs to be carefully estimated prior to 
offering surgery; especially, the presence of retinal pathol-
ogy and advanced glaucoma should be excluded. B-scan 
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ultrasonography must be performed to exclude retinal 
pathology. By and large, KPro patients cannot perform 
satisfactory visual field tests. The absence of light perception 
indicates poor prognosis, but an inaccurate light projection 
may be acceptable since it could be due to associated media 
opacities rather than posterior segment pathology. Electro-
physiological tests like electroretinogram and visual-evoked 
potential could be beneficial in doubtful situations, but they 
may also not be precise in quantifying the visual potential in 
the presence of media opacities and bilateral blindness.38,39 
History of regaining vision with previous surgical procedures 
is a good indication of visual recovery. In general, a KPro is 
offered to patients with bilaterally poor vision to the degree 
of hand moments or light perception. Only one eye should 
be offered a KPro, and the second eye should be kept as a 
spare and must be treated fully for glaucoma and other pathol-
ogy as appropriate in order to preserve the visual potential. 
Patients having both eyes suitable for KPro must be carefully 
counseled to choose the eye for KPro implantation. When 
OOKP is considered, particular attention should be paid to 
the orodental assessment.38,40
Patient counseling for KPro surgery should be aimed at 
determining the visual needs and general health status of the 
patient and to establish patient suitability and willingness to 
undertake the surgery. By this stage, the surgeon would ideally 
have determined and discussed with the patient about the choice 
of KPro device and surgical procedure, and its implications. 
The patient counseling session in our setup is undertaken with 
the help of a clinical psychologist. The psychologist assesses 
patient’s adaptation to the blindness, current life style and 
coping mechanisms, current employment, and social support 
in place. In our experience, a small number of patients have 
psychological morbidity, and addiction to alcohol and smok-
ing. These patients may require psychiatric and de-addiction 
treatments for better outcomes.41 During the counseling, it 
is important to determine patient suitability for the surgery 
and provide verbal and written information – explaining 
the steps for KPro surgery and changes to the life after the 
surgery – and most importantly, to establish realistic expecta-
tions with the patients. Also, the counselor offers help when 
the patient is not psychologically ready to accept surgery but 
is willing for it.41–43
In some patients, the primary medical illnesses contrib-
ute to the ocular surface disease such as Stevens–Johnson 
syndrome (SJS), bullous pemphigoid, and graft versus 
host disease (GVHD). This group of patients may have 
associated skin lesions, and mucosal disease in the urethra, 
pharynx, and esophagus predisposing them to the risks of 
anesthesia.44 A multidisciplinary team consisting of anes-
thetists, physicians, orodental, oculoplastics, vitreoretinal, 
and glaucoma surgeons is essential for optimum outcomes. A 
conscientious approach to patient expectations while offering 
psychological and social support, and ensuring provisions 
for patient access to the hospital facilities in emergency 
and planned follow-up care is crucial for the success of the 
service. Patient support groups, leaflets and written infor-
mation, clear instructions, and education of the patients and 
carers should form part of the care pathway. Implantation 
of the device is the first step to the patient’s journey through 
the KPro. Usually, these patients would have subsequent 
procedures performed to preserve the implant on the eye 
and to address the arising complications with time. Because 
patient follow-ups and postoperative care are a lifelong 
process, these procedures should only be offered at the spe-
cialist institutions having sufficient work force, experience, 
and resources in place.15,40
Soft KPros
In the recent past, a few devices based on soft polymers 
have progressed from the laboratory studies to human trials. 
The skirts and optics of these devices are made of softer 
materials.
AlphaCor KPro
The Lions Eye Institute in Australia developed a bio-integrable 
keratoprosthetic device made of poly-2-hydroxyethyl meth-
acrylate, otherwise known as the Chirila KPro.45 It was first 
implanted in humans in 1998 and was subsequently approved 
by the US Food and Drug Administration (FDA) in 2003.46 
Grossly, it resembles the natural cornea by having a central 
clear zone and a peripheral skirt. The central clear optical part 
is manufactured with reduced water content in the hydrogel, 
while the peripheral skirt is made of the same polymer but 
with a high water content. An interpenetrating network of 
polymers binds the two differing polymeric zones of the 
same compound.47 The main principle behind this device is 
that the outer skirt is integrable with the corneal tissue by 
the invasion of keratocytes, while the central zone remains 
optically clear (Figure 2A).
The AlphaCor is indicated when a corneal graft is per-
ceived as a high risk for failure as in cases with a history 
of prior graft failures. The device is generally offered only 
when the vision is reduced to 6/60 or light perception. There 
should be good retinal and optic nerve functions for visual 
regain. Advanced glaucoma is a relative contraindication.15 
The AlphaCor is generally suitable for eyes with adequate 
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Figure 2 AlphaCor keratoprosthesis.
Notes: (A) AlphaCor device. (B) First stage – insertion of AlphaCor within the corneal lamellar pocket. A 3 mm central zone part of the posterior lamella is trephined. (C) 
Second stage – the external portion of the optic is exposed by excision of the superior corneal lamella. Adapted by permission from Macmillan Publishers Ltd: Eye. Hicks CR, 
Crawford GJ, Lou X, et al. Corneal replacement using a synthetic hydrogel cornea, AlphaCor[trade]: device, preliminary outcomes and complications. 2003;17(3):385–392, 
Copyright ©2003.109
tear secretion. This device is supplied for aphakic, pseu-
dophakic, and phakic eyes separately. The survival of the 
device is poor in the presence of an active inflammation 
and recurrent herpes infection; hence; it should be avoided 
in those situations.48
AlphaCor device is implanted intrastromally into the 
cornea in two stages. In the first stage, a lamellar dissection 
is carried out from the superior limbus to create a lamellar 
pocket. An entry wound of 180°C width is created for access. 
The anterior and posterior lamellae are split into approximately 
50% thickness layers of each. The posterior layer is trephined 
with a 3.5 mm diameter trephine in the center to reach the 
anterior chamber. Then the prosthesis is inserted in between the 
two lamellae, and the superior layer is closed with interrupted 
sutures. At this stage, a conjunctival tissue flap can be overlaid 
if the corneal surface is uneven. Two to three months later, 
the second-stage procedure is performed with the anticipation 
that the host stromal fibroblasts would have grown into the 
matrix of the prosthesis. A 3.5 mm dermatological trephine is 
used to create an aperture through the anterior lamella, which 
completes the procedure and enables the patient to see through 
the prosthesis (Figure 2B and C).46
The AlphaCor has retention rates of 80% and 62% after 
the first and second years of follow-up, respectively, as found 
in a retrospective study of 322 cases by Hicks et al.46 They 
recommend an indefinite use of topical medroxyprogester-
one to enhance device retention. Despite its usage, stromal 
melts have occurred in 27% of their cases, out of which, 65% 
have resulted in device explantation.46 In a review involving 
15 AlphaCor implants, Jiraskova et al have reported a sur-
vival rate of 87% in the first year, 58% in the second, and 
42% in the third year of follow-up.48 Stromal melts occurred 
in 60% cases leading to device explanation in 33% of the 
total cases.48 Although the device is retained well in the first 
few years, the visual regain was affected by the occurrence 
of deposits on the optic and surface spoliation of the device 
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in up to 8.4%–20% of cases.46,48 Ngakeng et al have chosen 
to avoid the second stage of the procedure and left the surface 
layer of the cornea intact, since the majority of the complica-
tions happen after the stage 2.49 They reported a short series 
of six cases without a stage 2, and found no corneal melts 
or device extrusions at a follow-up range of 14–38 months. 
Conceivably, the visual regain was compromised with their 
approach, but they reported an improvement in postopera-
tive comfort and a reduction of complications. Owing to the 
risks of complications coupled with poor visual results and 
a growing popularity of the Boston KPro, the AlphaCor 
implant is a not a favored option nowadays.15
Legeais BioKPro-iii
Legeais BioKPro-III is a soft KPro, developed as an 
improvement over previous versions (II and III). It is made 
of polytetrafluoroethylene (PTFE), a porous opaque skirt, 
and polyvinylpyrrolidone-coated polydimethylsiloxane 
optic, which are chemically bonded together.50 This implant 
is similar in design to AlphaCor and is also inserted into 
the intralamellar space after dissection of the cornea in its 
mid-depth. The anterior lamella is trephined in the center to 
accommodate the optic, whereas the skirt is positioned into 
the periphery. Lens and iris tissue are removed as necessary. 
A conjunctival flap or, where it is deficient, a buccal mucosal 
patch is used to cover over the device. In a later stage, usually 
after 3 months, the covering tissues are excised with scissors 
to expose the optic. In a series published by Hollick et al six 
out of seven cases have failed due to exposure of the haptic, 
and in one case, it was totally extruded.50 In addition, all of 
these patients required further surgical revisions to stabilize 
the device. The authors conclude that there is no specific 
advantage of this device over the AlphaCor.
Hard KPros
PMMA is proven as the material of choice for the optical 
component of many KPros. Since it is a rigid polymer, the 
supporting skirt material has to be sufficiently resilient. 
Further, the bonding between the skirt and optic should be 
foolproof to withstand the IOP and forces generated through 
touch, blinking, and ocular movements. Highly porous and 
bio-integrable softer skirt materials like Dacron, Teflon, and 
Proplast were not proven to retain well on the eye.26,30,35 Per-
haps, harder materials should be preferred to make the skirts 
in the future KPro models. Moreover, rigid PMMA optic can 
easily be incorporated into the rigid, than the softer, skirts. 
The highly successful KPro models like Boston type-1 and 
OOKP are made of harder skirts.
Boston KPro
In the early 1950s, renewed interest was brewing in PMMA 
materials following the accidental discovery of their tolerabil-
ity in pilots’ eyes during the Second World War. Thereafter, 
many KPros were developed using PMMA as the core optical 
piece and other biomaterials as skirts.16 Since 1960, a pioneer-
ing research program began developing a KPro, which even-
tually resulted in the current model of Boston type-1 KPro 
(Massachusetts Eye and Ear Infirmary, Boston, MA, USA). 
The FDA approved this device in 1992. Previously known as 
the “Dohlman–Doane Keratoprosthesis”, the Boston KPro is 
made of rigid PMMA material in a collar-stud design. There 
is a type-2 version with indications from type-1 device.
Boston type-1 KPro
This is the most commonly used KPro in the world. It is 
a two-piece device. The front plate has a convex exterior 
surface and contains the optical stem. The back plate, made 
of PMMA, is a disk-shaped piece of 8.5 mm diameter with 
a central large aperture and 8–16 small diameter peripheral 
holes. Previous thread design of the stem is modified into 
a snug fit type.51 A titanium ring locks the back plate onto 
the stem. The latest design, which is also FDA approved 
for use in both types 1 and 2, has a modified back plate that 
eliminates the need for a locking ring and is available in 
both PMMA and titanium materials.52 A donor corneal but-
ton with a central trephination is sandwiched between the 
front and back plates, which acts as a carrier of the device. 
Fenestrations in the back plate allow aqueous to nourish 
the donor cornea (Figures 3A and 4).53 Boston type-1 KPro 
is available in standardized pseudophakic and customized 
aphakic models and can also be supplied with a small back 
plate (7 mm diameter) for pediatric use. The patients should 
wear a large diameter soft or contour contact lens for an 
indefinite period (Figure 3B). The contact lens protects the 
ocular surface from dryness, desiccation, and against corneal 
melting, ergo, it enhances device retention. Daily administra-
tion of vancomycin eye drops with or without broad-spectrum 
antibiotics like fluoroquinolones not only prevents infections 
but also defends against endophthalmitis.54
indications for Boston type-1 KPro
The Boston type-1 KPro is generally used as a corneal 
replacement in cases when corneal grafting is of high risk, 
and in the cases of corneal opacities with extensive vascular-
ization and repeat graft failures. Typical examples for such 
conditions include aniridia, certain corneal dystrophies and 
degenerations, herpetic keratitis, and corneal infections.55 
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Figure 3 Boston keratoprosthesis.
Notes: (A) Type-1 device with front plate (optical stem) and titanium back plate. (B) Type-1 device in situ with a bandage contact lens. (C) Type-2 device with extended 
optical stem and titanium back plate. (D) Type-2 device in situ – projection of the optical stem through the lid. All pictures of this figure are the courtesy of Dr James 
Chodosh.
An adequate tear secretion and ability to wear a soft contact 
lens are minimum requirements before considering Boston 
type-1 KPro. In addition, similar to any KPro procedure, 
patients should be able to attend regular follow-ups and 
comply with the postoperative treatment regimens.
Patient follow-up after Boston type-1 
KPro implantation
Patients are followed-up frequently in the early postoperative 
period, as such every week for the first month, then every 
2–3 weeks for 3 months, and every 3 months for the first 
year. Afterward, the follow-ups can be longer and based 
on the status of the eye. In each visit, visual acuity (VA) is 
recorded. Periodically, bandage lens must be removed and 
examined for corneal thinning and loosening of sutures, 
and a fluorescein dye is instilled to rule out leaks from 
the “prosthesis–cornea interface” and from the “cornea–
cornea interface”. Uniformity of the spread and fit of the 
bandage lens and its stability with blinks should be noted. 
The presence or absence of retroprosthetic membrane (RPM) 
ought to be checked and may be treated with YAG laser as 
necessary. IOP can be measured with digital palpation or 
with a Tonopen at the limbus. The fundus examination is 
essential, and visual fields should also be tested. Periodically 
removed bandage contact lenses may be sent for culture and 
sensitivity tests for microbiological surveillance. Prior to the 
contact lens replacement, betadine solution may be instilled 
and retained in the eye for several minutes as a measure to 
decrease the microbial load on the ocular surface. Any signs 
of corneal infiltrates or melts should be promptly addressed, 
which may otherwise result in serious infections and loss of 
the device, and perhaps eye (Figure 5A). Patients must be 
warned to return for lens replacement in case they are lost. All 
patients should receive broad-spectrum antibiotic eye drops 
like vancomycin or quinolones indefinitely. Topical steroids 
such as dexamethasone eye drops are usually administered 
along with the antibiotics for the short term. Their dosage 
and frequency are titrated and gradually weaned off based 
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Figure 4 Assembly and implantation of Boston type-1 KPro.
Notes: (A) Donor corneal button is trephined to create a central aperture. (B) Corneal graft is placed on the front plate. (C) PMMA back plate covers the graft and titanium 
ring locks the device. (D) Assembled type-1 device ready for implantation (corneal graft is sandwiched between the front and back plates). (E) Host cornea is excised (excised 
diameter matches outer diameter of the corneal graft). (F) Implantation of the type-1 KPro. All pictures of this figure are the courtesy of Dr Geetha Iyer.
Abbreviations: KPro, keratoprosthesis; PMMA, polymethylmethacrylate.
on the condition of the eye. Topical anti-glaucoma drops 
can also be administered in those patients with glaucoma. 
Preservative-free medications are usually preferred because 
of the presence of contact lens.
Outcomes of Boston type-1 KPro
In a multicenter descriptive case study, which included 
141 Boston type-1 procedures across 17 centers, Zerbe et al 
reported a postoperative increment in VA levels up to 20/200 
(Snellen equivalent 6/60) in nearly 57% of patients.56 In a 
case review involving 47 eyes with Boston type-1 KPro, 
Greiner et al report similar visual results; a 59% of patients 
have retained 20/200 VA over a year of follow-up.57 Aldave 
et al published a comparative case study involving various 
international centers with a cumulative number of 113 proce-
dures, against 110 procedures performed in one of the USA 
centers.58 They noted a preoperative VA level of 20/200 in 
2% of the patients from the international group and in 6% of 
the patients from the USA group, whereas postoperatively 
at 6 months, 70% of the international patients and 69% 
of the USA patients have regained a VA level of 20/200. 
However, the number of patients maintaining the same level 
of vision had gradually declined over 2 years to 59% and 
60%, respectively. Interestingly, the percentage of patients 
with pre- and postoperative VA of less than or equal to light 
perception was not changed significantly in both the groups 
(international: 50% preoperative versus 60% postoperative; 
USA group: 9% preoperative versus 10% postoperative).
Anatomical retention of the device is excellent in the 
short term. Zerbe et al report a 95% retention rate at an 
average of 8 months of follow-up.56 Chew et al report a 100% 
retention at 16 months in a cohort of 36 cases,59 whereas 
Aldave et al report an 84% retention at a 17-month follow-up 
for 57 prostheses in 49 patients.60 In the comparative series 
mentioned earlier, Aldave et al identifies a device retention 
rate of 80% at a mean follow-up period of 14 months in the 
international group against a similar retention rate of 80% 
at an average of 24 months in the USA group.58 Greiner et al 
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Figure 5 Postoperative course of the Boston type-1 KPro.
Notes: (A) Corneal graft melt adjacent to the front plate. (B) Retroprosthetic membrane seen through the optic. (C) OCT scan showing Boston type-1 KPro in situ. Pictures 
(A) and (B) are courtesy of Dr Geetha Iyer.
Abbreviations: KPro, keratoprosthesis; OCT, optical coherence tomography.
also reported an 80% retention rate at a mean follow-up of 
34 months.57 Bradley et al report an anatomical retention 
of 81% for 30 eyes with a mean follow-up of 19 months.61 
In eyes with successful implants, vision is affected by a 
number of factors in the postoperative period such as RPM, 
glaucoma, retinal detachment, endophthalmitis, and stromal 
melts.
An RPM is a proliferation of the fibrovascular tissue 
over the internal surface of the device, which can occlude 
the optical portion leading to visual obstruction (Figure 5B). 
It is usually treated with YAG laser, but some severe cases 
will require surgical membranectomy. Stacy et al reviewed 
the literature and noted an incidence of RPM in the range 
of 25%–65% with the Boston type-1 implants, of which 
nearly 45% required treatment with YAG laser or surgical 
membranectomy.62 They also performed a histological study 
and hypothesized that RPM is derived from corneal stromal 
downgrowth from the host side due to gaping of the posterior 
wound beyond the back plate. In addition, metaplastic lens 
epithelium and native iris stroma contribute to its develop-
ment. Magalhães et al in their review, identified a number 
of risk factors for the development of RPM, which include 
anterior segment inflammation, previous keratitis, and simul-
taneous performance of other intraocular surgeries at the time 
of KPro implantation.63
Implantation of a KPro can induce glaucoma and worsen 
the preexisting glaucoma. Distortion of angle structures, 
occurrence of RPM, and peripheral anterior synechiae have 
all been implicated as causes of glaucoma.64 According to 
Banitt, glaucoma is prevalent in up to 36%–76% of Boston 
KPro patients and de novo glaucoma developed in 2%–28% 
of the patients after the device implantation.65 Glaucoma man-
agement including its detection, monitoring, and treatment is 
a significant challenge for KPro surgeons. IOP measurement 
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is not possible with corneal applanation methods. Tonopen 
measurements taken at the limbus and comparisons with 
the fellow eye have been practiced; subjective estimation of 
IOP by digital palpation is an alternative, but both are less 
accurate. Monitoring of visual fields is also constrained due 
to the smaller size of the optical aperture, which provides 
limited field of vision. Optic disk photography and imaging 
with OCT or Heidelberg retinal tomography (HRT) can be 
useful modalities, but the disk changes can take longer time 
to develop, and significant field damage could happen in 
the meantime.
Topical glaucoma medication may be effective in 
reducing the IOP. Nevertheless, majority of the patients 
require surgical treatments such as glaucoma drainage 
device insertions (valved or non-valved) either along with 
or after the KPro implantation. Li et al studied 45 eyes after 
Boston KPro implantation and found that 17 eyes needed 
glaucoma drainage tube insertion.66 They also reported a 
59% incidence of conjunctival erosions following glau-
coma tube inserts in Boston KPro patients. In the same 
study, a 60% of eyes without “glaucoma device-associated 
conjunctival erosions” retained a VA of 20/200 and only 
a 25% of the eyes that suffered erosions could retain a VA 
of 20/200 at 1-year follow-up. The presence of glaucoma is 
associated with poor visual prognosis, and development of 
erosions and subsequent complications, such as hypotony, 
endophthalmitis, and choroidal and retinal detachments, 
may adversely affect visual potential of the eye.64,66 Never-
theless, prompt pre- and postoperative glaucoma manage-
ment with Boston KPro can improve visual prognosis.64 
Cyclophotocoagulation can be useful in those who do not 
respond to drainage tubes.67
Robert et al reviewed the literature on endophthalmitis 
following Boston KPro and found that its incidence ranges 
from 0% to 25%.68 Using a pooled data, they estimated the 
prevalence of endophthalmitis as 5.4% in the last 10 years 
with Boston type-1 KPro. The risk of endophthalmitis is 
generally considered high with inflammatory conditions like 
SJS, mucous membrane pemphigoid (MMP), and burns.69 
Although the current standard practice of daily administra-
tion of topical vancomycin has reduced the incidence of 
Gram-positive endophthalmitis, an increased incidence 
of Gram-negative bacterial and fungal endophthalmitis is 
observed by some investigators.61,70 In cases of endophthal-
mitis, device explantation followed by vitrectomy and 
intravitreal injection of broad-spectrum antibiotics is 
advised in view of the high incidence of posterior segment 
complications.68
Posterior segment complications like retinal detachment 
have been reported in the range of 3%–12%.56,71 Altered eye 
anatomy and the presence of a limited field of vision through 
the optic make vitreoretinal surgery a daunting task.
Despite the existence of various problems, there has been 
a steady increase (more than threefold) in the number of 
Boston type-1 KPro implantations performed in the USA and 
rest of the world.72 This may be largely due to the increase in 
device retention rates and awareness of the procedure.
Boston type-2 KPro
The less popular type-2 device is similar to type-1 in design 
except that it contains a longer optical stem that is intended to 
project through the lids. It is made for use in severe dry eyes. 
The ocular surface is divested of the entire forniceal and tarsal 
conjunctiva, and a notch is created in the upper lid margin to 
incorporate the extended optical stem, which protrudes beyond 
the lids. A complete and permanent tarsorrhaphy is performed 
to conceal the ocular surface along with the device bar the opti-
cal stem (Figure 3C and D). Patients with type-2 Boston KPro 
should also receive prophylaxis with daily topical antibiotic 
drops like vancomycin and fluoroquinolones. The type-2 KPro 
is reserved for extremely dry and cicatrizing ocular surface 
diseases like SJS, MMP, and chemical burns.
Pujari et al in a study involving 29 Boston type-2 KPro 
implants in 26 patients, reported that 57% of the patients 
retained a vision of 20/200 at 1 year.73 There was a high preva-
lence (70%) of preexisting glaucoma in their cohort. In the 
same series, incidence of RPM was 50%, retinal detachment 
was 28%, and endophthalmitis occurred in one case. Extru-
sions of the device were observed in 42% of the patients.
Recent advances in Boston KPro
According to Sivaraman et al, development of a thick RPM fol-
lowing Boston KPro is linked to the increased risk of corneal 
melts and subsequent KPro extrusions by impeding the aqueous 
flow, thereby decreasing corneal nourishment.74 Todani et al 
suggest that titanium back plates are associated with reduced 
incidence of RPM formation than PMMA back plates.75 Cru-
zat et al suggest that large titanium back plates of 9.5 mm 
diameter clamp the graft–host junction more effectively 
than the 8.5 mm diameter back plates and may reduce RPM 
formation.76
Anterior segment OCT imaging is a useful adjunct in 
KPro monitoring (Figure 5C). Pre- and postop imaging 
can identify patients at risk of developing synechial angle 
closure. It is also useful in characterization and monitoring 
of peripheral anterior synechiae and status of the angle.77 
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The high-resolution spectral domain OCT may also enable 
to study complications to the finer details such as RPM, 
epithelial downgrowth, stromal necrosis, and corneal 
thinning.78 Perhaps, OCT study of preoperative and peri-
prosthetic anatomy could lead to refinements of the design 
and techniques of Boston KPro device.
Collagen-cross-linked corneas of rabbits with  ultraviolet- 
A/riboflavin method are shown to be resistant to enzymatic 
degradation. It has been suggested that cross-linking of donor 
carrier corneal material could decrease the occurrence of 
keratolysis and device extrusion.79 Frozen donor materials 
and glycerin-preserved corneas have been suggested as car-
rier materials for Boston KPro.80
Frequent change of the contact lens and periodic admin-
istration of antifungal drops and, may be betadine instilla-
tion could minimize the risk of fungal and Gram-negative 
bacterial infections.81
Todani et al implanted a ring-shaped wireless IOP trans-
ducer (gold microchip and micro-coil antenna encapsulated in a 
silicone rubber) into the eyes of rabbits after extracapsular lens 
extraction.82 In their study, the device was well tolerated, and 
the measurements were reproducible and stayed in concordance 
with manometry. In a subsequent trial by the same group on a 
patient with open-angle glaucoma, the device was found to be 
well tolerated over a follow-up of  76 weeks. The IOP measure-
ments were also observed to be in concordance with Goldmann 
applanation tonometry.83 This device may have application in 
the management of glaucoma associated with KPros.
Osteo-odonto-keratoprosthesis 
(OOKP)
Scores of porous and nonbiological keratoprosthesis skirt 
materials were used, for example, Teflon (Cardona),23 Pro-
plast (Girard),24 ceramic (Polack),25 Dacron (Pintucci et al),28 
expanded PTFE (Legeais et al),31 hydrogel (AlphaCor),47 and 
hydroxy-apatite (León et al).84 Integration of these materials 
with the ocular tissues and longevity of the KPros was not 
impressive.30,35 Consequently, some investigators have tried 
to utilize autologous tissues for better integration of the KPro. 
Tooth root–alveolar bone complex (Strampelli-OOKP),85 
cartilage (Casey),86 and tibial bone (Temprano)87 were used 
as the biological alternatives for the KPro skirt. Cartilage is 
out of use now; however, tibial bone is used as an alternative 
in edentulous patients when OOKP is not possible.
OOKP surgical technique
OOKP surgery was invented by Strampelli and subsequently 
improved by Falcinelli et al 85,88 Details of the modified OOKP 
surgical technique are fully described in “Rome-Vienna 
Protocol”.38 The basic principle of OOKP involves bypassing 
the ocular surface with a patch of buccal mucous membrane 
(BMM) and replacement of the anterior segment structures 
with an osteo-odonto-acrylic lamina. The mucous membrane 
can withstand dry conditions of the environment and quickly 
regenerate after restoration of the moisture, and also survive 
over inflammation to some extent. The alveo-dental lamina 
integrates well with the ocular tissues and can retain for a 
number of decades in successful cases.89
OOKP surgery is a complex multi-stage procedure 
performed by experienced oral and ophthalmic surgeons. 
Normally, the patients are started on antiseptic and antifungal 
mouthwashes a day before the surgery. The first stage, which 
may also be performed in one or two sequential substages, 
involves laying of the buccal mucosa onto the prepared ocular 
surface and implantation of the alveo-dental-acrylic lamina 
into the submuscular pocket (Figure 6). The ocular surface 
preparation involves removal of the keratinized scar tissues 
and corneal epithelium and retraction of the conjunctiva to 
the fornices. A patch of buccal mucosa is excised and grafted 
to the prepared ocular surface bed. It is also anchored to the 
four recti muscles for vascular investment. Generally, in 
the same sitting, a single rooted healthy tooth – typically a 
canine – with a piece of surrounding mandible is harvested. 
The tooth-bone plate is trimmed, the crown is excised, and 
a PMMA optical cylinder is inserted through the central 
aperture in this plate (Figure 7). The axial length of the eye 
and surface area of the dentine determine the power and size 
of the optical cylinder. Thus prepared “osteo-odonto-acrylic 
lamina” is implanted into the subcutaneous pouch of the con-
tralateral lower lid (Figure 8A and B). The laminar prepara-
tion may also be performed at a later stage if the viability of 
mucous membrane is questionable. In edentulous patients, 
autografts from tibial bones or allograft teeth from related or 
unrelated living donors can be considered.38,40,87
The second stage is usually performed after 3 or 4 months 
to ensure naturalization of the oral mucosa over the ocular 
surface and to promote vascular ingrowth into the osteo-
odonto-acrylic lamina (Figure 8C). During this stage, the 
lamina is explanted from the lower lid and examined for 
erosions, bulk, and stability of the cylinder. It is rare to not be 
able to proceed further because of an inadequate or unstable 
OOKP lamina. By trimming off the excess connective tissue 
from the lamina, the dentine surface is exposed (Figure 9A 
and B). The mucous membrane is dissected from the sclera 
on the superior bulbar portion and reflected into the lower 
fornix to expose the cornea (Figure 9C). An appropriate 
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Figure 6 OOKP stage 1 – buccal mucosal graft preparation and transplantation.
Notes: (A) excision of the BMM. (B) excised mucosal tissue-fat and muscle are trimmed off. (C) Ocular surface preparation (sclera is bared and corneal epithelium 
debrided). (D) Mucosal graft transplantation on to the ocular surface.
Abbreviations: OOKP, osteo-odonto-keratoprosthesis; BMM, buccal mucous membrane.
Figure 7 OOKP stage 1 – tooth extraction and preparation of the OOAL lamina.
Notes: (A) extraction of the tooth with a piece of mandible. (B) Preparation of the tooth (dentine is exposed on one surface, while the alveo-dental ligament is preserved). 
(C) A central hole is drilled perpendicular to the lamina. (D) A PMMA cylinder is inserted into the lamina.
Abbreviations: OOKP, osteo-odonto-keratoprosthesis; OOAL, alveo-dento-acrylic; PMMA, polymethylmethacrylate.
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Figure 8 OOKP lamina and postoperative course after stage 1.
Notes: (A) PMMA optical cylinder – the wide part sits on the dentine surface. (B) Prepared OOAL lamina – rim of acrylic cement can be seen around the optic. (C) A healthy 
mucous membrane 1 month after the stage 1.
Abbreviations: OOKP, osteo-odonto-keratoprosthesis; PMMA, polymethylmethacrylate; OOAL, alveo-dento-acrylic.
diameter Flieringa ring is fastened to support the sclera. Any 
left-over corneal epithelium is removed, and the cornea is 
trephined in the center to create a 3–4 mm diameter aperture, 
which is extended by two opposite slit incisions (Figure 9D). 
The crystalline lens is removed by cryoextraction (Figure 
9E); if pseudophakic, intraocular lens is also removed with 
the bag in toto, redundant iris is removed from its root, and 
core vitrectomy is performed (Figure 9F). The lamina is 
implanted by insertion of the optical cylinder through the 
central corneal hole (having its dentine side sitting on the 
cornea). The lamina is anchored to the sclera with vicryl (6-0) 
sutures (Figure 9G). Cylinder positioning is assessed with 
an indirect ophthalmoscopic examination, and the sutures 
are adjusted accordingly to achieve centrality. The whole 
lamina should be tightly secured. The BMM is closed with 
interrupted absorbable sutures. An opening is made in the 
center of BMM, through which the optical cylinder projects 
up to 2 mm (Figure 9H).38,40
Aseptic precautions must be observed while handling 
the tissues. The mucous membranes should always be kept 
moist. The osteo-odonto lamina is to be stored in the heparin-
ized blood during the transit. Prophylactic broad-spectrum 
antibiotics, intravenous acetazolamide, and mannitol are 
given during the operations to reduce the risk of subchoroidal 
hemorrhage.40
indications and contraindications 
for OOKP
Full details of the OOKP surgery including indications, 
investigations, patient assessment, and postoperative care 
can be accessed from Liu C et al.40 OOKP is indicated for 
eyes with defective lids and blinking, surface keratinization, 
and severe inflammatory conditions of the ocular surface 
such as: SJS, MMP, chemical and thermal burns, Lyell syn-
drome, trachoma, GVHD, and Sjögren’s syndrome.88 OOKP 
is not suitable for children due to the high bone turnover. It 
is contraindicated in phthisis bulbi and eyes without light 
perception.38,40
Patient assessment for OOKP
The patient assessment process in our institution (Sussex 
Eye Hospital, Brighton, UK) is similar to that mentioned 
under the “General considerations for KPro surgery” section. 
A multidisciplinary team comprising of ophthalmologists, 
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Figure 9 OOKP stage 2 – retrieval of the lamina and implantation into the eye.
Notes: (A) Lamina is recovered from the subcutaneous pocket. (B) Connective tissue is removed from the lamina to expose the dentine side. (C) Buccal mucosa from 
the eye is reflected to expose the cornea. (D) Central corneal button is excised. (E) Lens extraction (iOL is also removed when present). (F) Open sky core vitrectomy 
is performed. (G) Lamina is implanted into the eye with wide portion of the optical stem passing through the cornea. (H) Mucosal membrane is replaced over the lamina. 
Through a central opening in the BMM, the optic projects beyond 1 mm.
Abbreviations: OOKP, osteo-odonto-keratoprosthesis; BMM, buccal mucous membrane; iOL, intraocular lens.
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oral surgeons, anesthetists, nurses, and a clinical psychologist 
assesses patients referred for KPro surgery to our institute. 
The aim of the assessment is to establish the suitability of 
the patients for OOKP surgery, to identify the risk factors 
that could influence the surgical outcomes, and to provide 
information to the patient and family. The ophthalmologist is 
the initial point of patient assessment. During this consulta-
tion, the underlying pathology is determined, and the status 
of the eyes is evaluated as mentioned earlier. The eye for 
the proposed surgery is chosen based on the potential for 
success and patient’s preference. In the same visit, a short 
examination of the oral cavity and dentition is performed, 
general health is evaluated, and patients are subsequently 
referred to the oral surgeon and clinical psychologist if they 
are found suitable for OOKP surgery.
The oral surgeon assesses and selects the teeth based on 
clinical and radiological examination of the patient’s oral 
cavity. An orthopantomogram is usually performed. Some 
patients have poor dental cleanliness and oral health because 
of the co-existing disease of the oral cavity, for example, 
SJS. These patients are advised to improve oral hygiene and 
stop smoking if applicable. For edentulous patients, related 
or unrelated tooth donors may be considered and screened 
as required.
The clinical psychologist’s assessment is pivotal in our 
practice. Patients are thoroughly investigated for their psy-
chological and general health by the multidisciplinary team. 
Patients are educated about the OOKP surgery and provided 
with printed leaflets. Surgery is generally offered to patients 
with bilateral poor vision. The eye with a good visual poten-
tial is usually selected. Subsequent visits are planned to help 
the patients to arrive at a decision. The family members, 
patient carers, and tooth donors (if any) are also consulted. 
Once a decision is made for the surgery, they are referred to 
the anesthetist for assessment.
Follow-up after the OOKP Surgery
After the OOKP procedure, patient’s follow-up is lifelong. 
After each stage of the procedure, patients are usually seen 
every week in the first month and every month for the next 
3 months, and the further follow-up intervals are prolonged 
based on their progress. At every procedure, broad-spectrum 
antibiotics, oral acetazolamide, and steroids are given for a 
week, and patients are nursed in the hospital for a minimum of 
1 week. Patients should be warned before the stage 1 OOKP 
surgery that their vision could be further reduced because of 
the mucosal overlay on the cornea. In the early weeks after 
the stage 1, they are closely monitored for mucosal graft 
viability on the eye. They receive a broad-spectrum antibi-
otic eye ointment for three to four times a day to lubricate 
the mucosa. A conformer is also placed over the mucous 
membrane to prevent formation of adhesion bands. Patients 
are encouraged to do wide mouth opening exercises, and 
massage the cheek area externally over the site of mucosal 
harvestation to prevent stricture formation.
IOP measurement by tactile method and B-scan ultra-
sonography must be performed. Any raise in IOP should be 
treated with oral acetazolamide or a glaucoma tube.
In the later weeks, BMM over the ocular surface is 
inspected for ulcers, thinning, and infections. Any pathology 
should be promptly attended. If patients develop mucosal 
complications and require further treatments, it could delay 
undertaking of the stage 2. Leaving the lamina for longer 
than 3 months in the submuscular pouch can result in laminar 
resorption even before proceeding to the stage 2. It could 
necessitate a new lamina preparation, consequently leading 
to repetition of stage 1. Therefore, every effort should be 
made to promptly address mucosal complications and not 
to prolong the waiting time for stage 2.
Inspection of the lamina implantation site, on the con-
tralateral lower lid, is not to be forgotten. Lamina should be 
palpated at each visit; the presence of tenderness or swell-
ing over the laminar site may denote infection. If infection 
develops, it should be treated with broad-spectrum systemic 
antibiotics and may require laminar removal. An infected 
lamina may not be suitable for implantation into the eye 
because of the risk of endophthalmitis or its resorption.
In subsequent visits after the second stage, VA, mucosal 
health, laminar bulk, optic stability, and IOP are checked 
(Figure 10A). Fundus examination may not be possible in the 
early days after the stage 2 due to the presence of hemorrhage 
and air in the vitreous. Three or four months following the 
second stage, patients are advised to visit their opticians for 
refractive assessment and spectacle correction. We expect a 
change in the refractive status by that period due to loosening 
of the sutures and re-expansion of the globe. A rapid or a 
large change in refractive error occurring after this period 
may be due to migration of the optic or lamina as a result of 
laminar resorption. Periodic computerized tomography (CT) 
scanning of the lamina is performed to monitor its dimensions 
and volume.
Allograft patients are normally started on oral cyclosporine 
in the immediate postoperative period; however, the optimal 
dosage and duration of such treatment are unknown. 
Cyclosporine serum trough levels between 100 ng/mL 
and 200 ng/mL are maintained for allograft patients in our 
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Figure 10 Postoperative course after stage 2.
Notes: (A) A healthy OOKP eye after a successful surgery. (B) CT scan image showing an intact lamina in the OOKP eye.
Abbreviations: OOKP, osteo-odonto-keratoprosthesis; CT, computerized tomography.
practice. We also prescribe oral biphosphonates for patients 
with early laminar resorption and allografts in the anticipa-
tion of protection against laminar loss. There is insufficient 
follow-up data to verify the effect of this strategy. Patients 
being maintained on cyclosporine, oral steroids, and aceta-
zolamide over the long term should be monitored for their 
side effects in liaison with their local physicians.40
Outcomes of OOKP
Long-term anatomical retention of the OOKP is excellent 
across the major published studies. Liu et al reported an 81% 
probability of retaining laminar autografts over 5 years from a 
cohort of 36 cases,90 whereas the 5-year probability of retain-
ing allografts was nil from his cohort. The median survival 
of OOKP allografts was 30 months in their series. Marchi 
et al reported a 98% retention of the lamina in 85 patients 
over a 20-year follow-up.91 Falcinelli reported an 80% prob-
ability of laminar retention in 224 cases over a follow-up of 
18 years.92 From Michael et al’s report, 10-year anatomical 
survival of 145 OOKP and 82 tibial KPro implants was 
66% and 47%, respectively.93 Hille et al reported 100% 
retention of OOKP laminae in a 5-year follow-up.94 
Iyer et al reported a 96% anatomical success of OOKP lami-
nae in 50 cases with a mean follow-up of 15 months.95
A major cause for anatomical failure of the OOKP is lami-
nar resorption. Liu et al noted that laminar resorption occurred 
in 19% of their cases.90 Iyer et al reported laminar resorption 
in 22% of patients.95 De La Paz et al reported a laminar 
extrusion of 28%.96 Resorption results in decreased thick-
ness and defects in the lamina. When resorption involves the 
central aperture of the lamina, the optic cylinder can become 
loose and unstable, which can eventually result in aqueous 
leak, altered refraction, tilting of the lamina with change of 
visual axis, and endophthalmitis leading to catastrophic visual 
loss. Clinical detection of laminar resorption can be difficult 
until late sequelae such as laminar tilt and loosened cylinder 
have developed. In some cases, endophthalmitis may be the 
first clinical manifestation of laminar resorption.
Serial imaging of the lamina and comparison of its 
dimensions with CT or electron beam tomography can 
detect resorption early (Figure 10B).97 Stoiber et al proposed 
that evaluation of laminar linear dimensions on serial CT 
reconstruct images could identify resorption.98 However, 
their method is not entirely objective and there is an ele-
ment of operator-induced subjectivity and data may not be 
reproducible. In a retrospective study, Sipkova et al applied 
an automated algorithm called “Advanced Lung Analysis 
Software” on UK national cohort of OOKP patients and 
analyzed laminar volumes objectively from the serial mul-
tidimensional CT images.99 This method is reproducible and 
identified resorption earlier than clinical examination in 60% 
of the patients. Early detection of resorption could help the 
clinicians to monitor the rate of bone loss and enables to 
intervene at the correct opportunity. Risk factors for laminar 
resorption include allografts, young age (contraindicated in 
less than 17 years), tibial lamina, persistent inflammation, and 
perhaps smoking and use of steroids.38,40,87,89,90,93,97 Patients 
with these risk factors should be watched more closely.
In a systematic review, Tan et al conclude that across the 
published studies, 52% of patients achieved a VA better than 
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6/18 after OOKP and tibial lamina implantations.89 Liu et al 
gave an account of visual results from the UK and stated that 
out of a total of 36 patients, 78% have achieved a VA of 6/60 
or better and 53% achieved 6/12 or better.90
Tan et al and Hille et al reported intraoperative vitreous 
hemorrhage in nearly 50% of their cases.89,94 In the early 
postoperative period, the main causes for slow regain of 
VA are the presence of air bubble and hemorrhage in the 
vitreous. In our experience, some patients could take three 
to six months to develop cortical adaptation to vision. 
Elderly and those with a longstanding blindness before 
the OOKP operation should be prepared for delayed 
visual recovery.
In anatomically successful OOKP eyes, the main cause 
of visual loss is glaucoma. Glaucoma occurrence varies 
across the studies as identified by Tan et al in their review 
(Hille – 16%, De La Paz – 17%, Iyer – 20%, Marchi – 33%, 
Tan – 34%, Liu – 47%).89 In Falcinelli’s series, incidence 
of de novo (true postoperative) glaucoma was 10%.92 In a 
recent retrospective review of our unpublished data from the 
UK national cohort of OOKP patients involving 47 cases, 
we identified that 40% had pre-existing glaucoma, and 15% 
developed de novo glaucoma following the OOKP operation. 
Topical treatment with eye drops has only a limited role in 
treating OOKP eyes. In our experience, oral acetazolamide, 
sublingual administration of timolol eye drops, and oral 
beta-blockers have some beneficial effect on lowering the 
IOP. Surgical treatment is usually with the drainage tubes 
or ciliary body ablation using either transscleral or endo-
scopic lasers. Insertion of glaucoma tubes is normally not 
performed at the time of OOKP surgery to avoid hypotony, 
which may jeopardize laminar stability before it integrates 
with the sclera. Baerveldt implants may be considered for 
simultaneous surgery by temporarily occluding the lumen 
with sutures. However, insertion of any drainage device is 
fraught with difficulties due to lack of clear anatomical land-
marks. In addition, the effect of the device is compromised 
by thick BMM that impedes episcleral drainage.
Detection and monitoring of glaucoma is difficult in 
OOKP eyes similar to other KPros. Objective measurement 
of IOP in OOKP eyes with instruments is not possible. 
Therefore, digital IOP measurement by the clinician, disk 
assessment clinically and by serial disk imaging with pho-
tography, OCT, or HRT, and periodic visual field testing are 
useful in glaucoma assessment.100 In a study by Falcinelli 
et al the pattern electroretinogram amplitudes and contrast 
sensitivities are reduced in OOKP patients.101 Visual-evoked 
potentials are significantly reduced in glaucoma patients 
with OOKP compared to normal OOKP subjects.101 In our 
experience, some patients report eye pain and frontal head-
ache associated with raised IOP that is relieved after starting 
or increasing the uptake of oral acetazolamide. Complaints 
of reduced vision and eye pain should raise the suspicion 
of increased IOP in OOKP patients, particularly in de novo 
glaucoma cases.
RPM developed in 1%–7% in studies with large number 
of patients,92,96 compared to 17%–20% in smaller studies.89,90 
RPM generally requires YAG laser treatment similar to 
capsulotomy. In resistant cases, surgical membranectomy 
may be indicated. In severe cases, an exchange of lamina 
may be necessary.
Hughes et al reported a 23% incidence of vitreoreti-
nal complications from the UK cohort of 35 patients that 
included vitreous hemorrhage (three cases), retinal detach-
ments (three cases), and sequelae of endophthalmitis (three 
cases).102 Pars plana vitrectomy was performed in these 
patients through a temporary KPro using binocular indirect 
viewing system or under endoscopic guidance.102 Tan et al 
found a variable incidence of retinal detachment, 3%–26%, 
across the studies and a 6% in their own series.89,103 Manag-
ing vitreoretinal complications can be challenging because 
of the limited view and glare through the optic, and hence 
requires higher surgical expertise.
Oculoplastic complications account for a majority of 
the surgical procedures performed on OOKP eyes. Among 
the reported studies, mucosal complications were low-
est at 8% in Falcinelli’s study and highest in Hille et al’s 
study at 48%.89,92,94 Liu et al and Tan et al reported mucosal 
complications in 28% and 25% of their cohort of cases, 
respectively.89,90 The type of cases and the risk factors vary 
among these studies that may explain the differences in 
mucosal complications. Ulceration of the mucous membrane 
usually occurs due to inadequate vascularization of the graft 
on the ocular surface. These problems are usually treated with 
a bucket-handle flap, tarsal pedicle flap, or a new mucosal 
patch graft. Mucosal membrane overgrowth was reported in 
the literature by Iyer et al95 in 2%, by Liu et al90 in 33%, and 
by Tan et al89 in 22% of the cases. Mucosal overgrowth is nor-
mally treated by surgical excision. In recurrent cases, mucosal 
trimming and mitomycin-C application around the optical 
cylinder prevented mucosal regrowth in our experience.104 
Intraoperative oral complications were reported in nearly 
1%–3% of cases in Rome series.92
The incidence of endophthalmitis was lowest in 
Falcinelli’s series at 2%.92 Liu et al reported an 8% incidence 
of endophthalmitis in their cohort.90 However, their series 
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contained OOKP allografts. Endophthalmitis risk is high 
in the post-laminar implantation period either following a 
surgical procedure or because of laminar resorption. Risk 
factors for endophthalmitis in an OOKP eye include laminar 
resorption with loosening of the optic, indwelling glau-
coma tubes, and noncompliance with antibiotic ointment. 
Resorption can lead to expansion of the laminar foramina 
that creates a potential conduit for microbial entry into the 
globe. The risk of endophthalmitis may be low in OOKP 
eyes since there is no use of contact lens or corneal melt. 
Patients with acute endophthalmitis usually present with pain 
and visual loss. Its treatment may require laminar explanta-
tion, vitrectomy, and injection of intravitreal antibiotics. The 
prognosis is poor.97
Seoul (S-KPro)
Latest iteration of this KPro, developed by Kim et al includes 
an umbrella-shaped skirt made of polyurethane and nonwo-
ven polypropylene, whereas the primary model of this device 
included an expanded PTFE skirt.105 The optic is made of 
PMMA, which also harbors two polypropylene haptics. The 
skirt is fixed into the intralamellar corneal pocket, while the 
haptics are fixed to the sclera by ab interno insertion. Kim et 
al have published the outcomes of their device in nine eyes 
with an average follow-up of 63 months. All of the cases 
had exposure of the skirt, and device exchange was needed 
in four eyes.105
KPros with titanium skirt
Titanium has been in use for biomedical applications for a 
long time. Its use in keratoprosthetic applications dates back 
to five decades. Apart from the recent Boston KPro model, 
which has a titanium back plate, KPros based on titanium 
metallic skirts have been in use from a long time in Russia, 
Ukraine, and the People’s Republic of China.
KPro at Filatov institute, Ukraine
Filatov institute in Ukraine has been involved in the develop-
ment of a KPro since 1966.106 They used titanium flanges to 
support the PMMA optic, and thus a range of designs were 
developed at their center (Figure 11). The newest variety of 
their device, “Iakymenko–Golubenko model”, consists of 
a central titanium ring, which bears the threaded optic, and 
three small ring-shaped flanges attached on its outside. This 
KPro is implanted in two stages. In the first stage, the device 
is fixed ab interno; the flanges are inserted into patient’s 
corneal lamellae and optic into the anterior chamber. The 
anterior corneal lamella is retained for 3–6 months to cover 
the optic and establish the device inside the eye. In the sec-
ond stage, the anterior corneal lamella is excised over the 
front surface of the optic, which then enables the patient 
see through. The host cornea is strengthened externally to 
endure the metallic skirts by the addition of corneal graft 
or oral mucosal tissue. Intralamellar strengthening is also 
achieved in some cases by using a donor lamellar corneal 
Figure 11 Filatov keratoprostheses.
Notes: (A–F) show the previous models. Model (G) is the latest and most successful Iakymenko prosthesis. Reproduced from Iakymenko S. Forty-five years of keratoprosthesis 
study and application at the Filatov institute: a retrospective analysis of 1060 cases. Int J Ophthalmol. 2013;6(3):375–380, doi:10.3980/ j.issn.22223959.2013.03.22.106
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graft, or dura mater or autologous auricular cartilage. 
Iakymenko published the results of different models of KPros 
implanted in 1,060 eyes between the years 1972 and 2010 
at their institute.106 With his latest design of dismountable 
threaded optic, as mentioned above, and by strengthening 
of the host cornea, he projects a steep reduction in corneal 
melts from 29% to 3% and device extrusions from 17% to 
1.5%. The exact duration of follow-up is not clear from his 
publication. He proposes that his device has a success profile 
similar to that of Boston type-1 KPro and OOKP and is suit-
able for dry and wet eyes. A multicenter study with long-term 
follow-up may establish this interesting prosthesis.
MiCOF KPro
Moscow Eye Microsurgery Complex in Russia (MICOF) 
KPro, which is used in Beijing, People’s Republic of China, 
is similar to the Ukrainian KPro in material composition and 
built.107 It has a titanium frame of two ear-shaped flanges 
and a central ring. The ring incorporates a threaded PMMA 
optic. This device is also implanted in two stages. During the 
first stage, the titanium frame, with a filling material inside 
the ring, is implanted into the corneal lamella. In the second 
stage, the cornea is trephined, filling material is removed, 
and posterior corneal lamella is trephined inside the central 
titanium ring. The PMMA optic is screwed inside the ring 
to reach the anterior chamber. The procedure is completed 
by a pars plana vitrectomy combined with removal of the 
lens and iris. Huang et al published the results of 85 cases 
of MICOF KPro.107 Their series contained a large number 
(82%) of patients with chemical and thermal injuries, and 
the remainders were autoimmune diseases. They projected 
a device retention rate of 81% at a mean follow-up of 
35 months. They also stated that none of the devices were 
explanted, but 19% of the cases required tissue augmentation 
to retain the implant. There was a high incidence of RPM 
(46%) in their cohort. Although authors have used autologous 
auricular cartilage to strengthen the cornea, use of this device 
in cases with previous perforations and corneal grafts may 
be difficult. Likewise, a multicenter study with a longer term 
follow-up may establish the success of this KPro.
Fyodorov–Zuev KPro
Another device similar to MICOF KPro, namely Fyodorov–
Zuev KPro, is made of two ear-shaped titanium flanges 
having large holes and a central titanium ring with internal 
threading that matches with the external threading of the 
PMMA optical cylinder. This device is first inserted into 
the lamellae of a donor cornea which is then implanted into 
the eye akin to a standard penetrating keratoplasty. The lens, 
iris, and mid-vitreous are also removed in the same sitting. 
The entire complex may be covered by conjunctival flap or 
labial mucosa. Ghaffariyeh et al published a series of ten 
cases using this device with a follow-up ranging between 
28 months and 84 months.108 The device was retained only 
in seven cases. Its success was limited by complications like 
corneal necrosis around the central piece and poor integration 
leading to aqueous leaks, hypotony, and endophthalmitis.
Essentially, the titanium devices are implanted within 
the corneal lamellae. These prostheses may find applica-
tion in cases, where corneal strength is adequate to support 
the device. Although the authors have adapted to corneal 
strengthening procedures by adding exogenous or autolo-
gous materials, integration and longevity of the device are 
questionable in conditions such as thin corneas, previous 
perforations, existing corneal grafts, and recurrent herpetic 
keratitis. Nevertheless, these devices could be considered as 
alternatives to OOKP when patients have no suitable teeth.
Conclusion
The Boston type-1 and OOKP are the two KPros with a 
proven record of success among numerous devices that 
came into human use. They have rapidly gained popularity 
across the world. Boston type-1 KPro is widely considered 
as the device of choice to restore vision in “wet-blinking 
eyes”, and OOKP for eyes with dryness and defective lids 
and blinking.
The Boston KPro has the advantage of easy repeatability 
in cases of device failure since it is available off the shelf. Yet, 
it requires a donor cornea as a carrier. OOKP is a complex 
multi-stage procedure, which is time and resource hungry. In 
comparison to OOKP, Boston type-1 KPro surgical proce-
dure is technically less challenging but has a less follow-up 
record. OOKP, with a well-established long-term success, is 
the “gold standard KPro”, against which other KPros should 
be evaluated.
Edentulism is common in elderly and patients with oral 
mucosal diseases. Lack of suitable dentition is a limitation for 
a number of patients in need of OOKP surgery. Ophthalmolo-
gists involved in the management of patients who are poten-
tial candidates for future OOKP surgery should pay attention 
to the oral care of the patients, and may perhaps involve 
dentists early on the course of patient management.
Patient selection is crucial for successful outcome with 
any KPro surgery. Patients considering a KPro should be 
able to accept possible complications, further operations, 
and frequent hospital visits. They should also be able to 
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recognize sudden changes in their conditions and present 
quickly to the hospitals for emergencies. Psychological and 
social support is of paramount importance in the patient care. 
The level of available social care and capacity for self-care 
must be clearly evaluated before offering the KPro procedure. 
After a prosthesis implantation, patient follow-up is lifelong. 
Selection of the correct device for the correct patient, with 
due consideration of the underlying diagnosis and morbid-
ity of the eye, is fundamental for best outcomes. Switching 
patients from one device to other after an implantation may 
not be possible.
After a successful KPro implantation, further surgical 
revisions will be required to retain the prosthesis and to 
treat complications. Despite these measures, glaucoma can 
adversely affect the long-term visual outcome. Therefore, a 
KPro should be considered as a non-permanent restoration 
of sight at this point of time.
PMMA has largely solved the need for a stable and bio-
compatible optical component of KPros. Nonetheless, the 
anchoring skirt material is still an area that requires research. 
We envisage that with rapid advances in biomaterial science 
and surgical techniques, and the success of the KPros and 
their longevity will continue to improve.
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